Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OM336 · 2 trials · 5 indications
Incidence and severity of treatment-emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| OM336 Dose Escalation | EXPERIMENTAL | Participants will receive OM336 via subcutaneous injection in ascending dose cohorts |
| Name | Type | Description |
|---|---|---|
| OM336 | DRUG | OM336 is an engineered bispecific antibody directed against BCMA and CD3 |
Key Inclusion Criteria: * Diagnosis of active seropositive autoimmune disease * Relapsed/refractory after ≥2 prior/ongoing treatments * Body weight ≥ 50 kg * Willing to comply with and study requirements and procedures Key Exclusion Criteria: * Previous treatment with a BCMA-targeted therapy * Cl...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Ianalumab |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE3 | Obexelimab |
| Rigel Pharmaceuticals, Inc. | RIGL | 1 | PHASE3 | Fostamatinib disodium |
| Johnson & Johnson | JNJ | 1 | PHASE2 | M281 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | rilzabrutinib |
| HUTCHMED (China) Limited Sponsored ADR | HCM | 1 | PHASE2 | HMPL-523 |
| Vertex Pharmaceuticals Incorporated | VRTX | 1 | PHASE1 | povetacicept |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX112 |